Drug General Information
Drug ID	D0X2UI
Former ID	DIB012317
Drug Name	LIK-066
Indication	Type 2 diabetes [ICD9: 250; ICD10:E11]		Phase 2	[524252]
Company	Novartis AG
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Sodium/glucose cotransporter 1	Target Info	Inhibitor	[543973]
KEGG Pathway	Carbohydrate digestion and absorption
	Bile secretion
	Mineral absorption
PathWhiz Pathway	Lactose Degradation
	Trehalose Degradation
Reactome	Hexose transport
	Na+-dependent glucose transporters
	Inositol transporters
WikiPathways	NRF2 pathway
	Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
	Metabolism of carbohydrates
References
Ref 524252	ClinicalTrials.gov (NCT01824264) Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes. U.S. National Institutes of Health.
Ref 543973	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.